Weaver, R. J. & Valentin, J. P. Today’s challenges to de-risk and predict drug safety in human “Mind-the-Gap”. Toxicol. Sci. 167, 307–321 (2019).
Article CAS PubMed Google Scholar
Moggs, J. et al. Investigative safety science as a competitive advantage for Pharma. Expert Opin. Drug Metab. 8, 1071–1082 (2012).
Beilmann, M. et al. Optimizing drug discovery by investigative toxicology: current and future trends. ALTEX 36, 289–313 (2019).
ICH Topic -M3 (R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (European Medicines Agency, 2009).
Roberts, R. A. Understanding drug targets: no such thing as bad news. Drug Discov. Today 23, 1925–1928 (2018).
Favuzza, P. et al. Dual plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle. Cell Host Microbe 27, 642–658 e612 (2020).
Article CAS PubMed PubMed Central Google Scholar
Zuhl, A. M. et al. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of beta-secretase inhibitors. Nat. Commun. 7, 13042 (2016).
Article CAS PubMed PubMed Central Google Scholar
Barber, J. et al. A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria. Toxicol. Res. 10, 203–213 (2021).
Siintola, E. et al. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 129, 1438–1445 (2006).
Ramirez-Montealegre, D., Rothberg, P. G. & Pearce, D. A. Another disorder finds its gene. Brain 129, 1353–1356 (2006).
Hornberg, J. J. et al. Exploratory toxicology as an integrated part of drug discovery. Part II: screening strategies. Drug Discov. Today 19, 1137–1144 (2014).
Article CAS PubMed Google Scholar
Hornberg, J. J. et al. Exploratory toxicology as an integrated part of drug discovery. Part I: why and how. Drug Discov. Today 19, 1131–1136 (2014).
Article CAS PubMed Google Scholar
Atienzar, F. A. et al. Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans. Toxicol. Appl. Pharm. 275, 44–61 (2014).
Atienzar, F. et al. Investigative safety strategies to improve success in drug development. J. Med. Dev. Sci. 2, 2–29 (2016).
Lin, Z. W. & Will, Y. Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol. Sci. 126, 114–127 (2012).
Article CAS PubMed Google Scholar
Langhans, S. A. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front. Pharmacol. 9, 6 (2018).
Article PubMed PubMed Central Google Scholar
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P. & Tagle, D. A. Organs-on-chips: into the next decade. Nat. Rev. Drug Discov. 20, 345–361 (2021).
Article CAS PubMed Google Scholar
Natale, A. et al. Technological advancements for the development of stem cell-based models for hepatotoxicity testing. Arch. Toxicol. 93, 1789–1805 (2019).
Article CAS PubMed Google Scholar
Baudy, A. R. et al. Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab Chip 20, 215–225 (2020).
Article CAS PubMed Google Scholar
Vulto, P. & Joore, J. Adoption of organ-on-chip platforms by the pharmaceutical industry. Nat. Rev. Drug Discov. 20, 961–962 (2021).
Article CAS PubMed Google Scholar
McAleer, C. W. et al. On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships. Sci. Rep. 9, 9619 (2019).
Article PubMed PubMed Central Google Scholar
Vo, A. H., Van Vleet, T. R., Gupta, R. R., Liguori, M. J. & Rao, M. S. An overview of machine learning and big data for drug toxicity evaluation. Chem. Res. Toxicol. 33, 20–37 (2020).
Article CAS PubMed Google Scholar
Hunter, F. M. I. et al. Drug safety data curation and modeling in ChEMBL: boxed warnings and withdrawn drugs. Chem. Res. Toxicol. 34, 385–395 (2021).
Article CAS PubMed PubMed Central Google Scholar
Ferreira, S. et al. Quantitative systems toxicology modeling to address key safety questions in drug development: a focus of the TransQST consortium. Chem. Res. Toxicol. 33, 7–9 (2020).
Article CAS PubMed Google Scholar
Weaver, R. J. et al. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. Expert. Opin. Drug Met. 13, 767–782 (2017).
Atienzar, F. A. et al. Key challenges and opportunities associated with the use of in vitro models to detect human DILI: integrated risk assessment and mitigation plans. Biomed. Res. Int. 2016, 9737820 (2016).
Bell, C. C. et al. Transcriptional, functional, and mechanistic comparisons of stem cell-derived hepatocytes, HepaRG cells, and three-dimensional human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury. Drug Metab. Dispos. 45, 419–429 (2017).
Article CAS PubMed PubMed Central Google Scholar
Hart, S. N. et al. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab. Dispos. 38, 988–994 (2010).
Article CAS PubMed PubMed Central Google Scholar
Rogue, A., Lambert, C., Spire, C., Claude, N. & Guillouzo, A. Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells. Drug Metab. Dispos. 40, 151–158 (2012).
Article CAS PubMed Google Scholar
Castell, J. V., Jover, R., Martinez-Jimenez, C. P. & Gomez-Lechon, M. J. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert. Opin. Drug Met. 2, 183–212 (2006).
Sison-Young, R. L. et al. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch. Toxicol. 91, 1385–1400 (2017).
Article CAS PubMed Google Scholar
Kamalian, L. et al. The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death. Toxicol. Vitr. 29, 732–740 (2015).
Jang, K. J. et al. Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci. Transl. Med. 11, eaax5516 (2019).
Article CAS PubMed Google Scholar
Proctor, W. R. et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch. Toxicol. 91, 2849–2863 (2017).
Article CAS PubMed PubMed Central Google Scholar
Whitebread, S. et al. Secondary pharmacology: screening and interpretation of off-target activities - focus on translation. Drug Discov. Today 21, 1232–1242 (2016).
Article CAS PubMed Google Scholar
Whitebread, S., Hamon, J., Bojanic, D. & Urban, L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10, 1421–1433 (2005).
Article CAS PubMed Google Scholar
Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909–922 (2012).
Article CAS PubMed Google Scholar
Valentin, J. P. et al. In vitro secondary pharmacological profiling: an IQ-DruSafe industry survey on current practices. J. Pharmacol. Toxicol. Methods 93, 7–14 (2018).
Article CAS PubMed Google Scholar
Jenkinson, S., Schmidt, F., Rosenbrier Ribeiro, L., Delaunois, A. & Valentin, J. P. A practical guide to secondary pharmacology in drug discovery. J. Pharmacol. Toxicol. Methods 105, 106869 (2020).
Article CAS PubMed Google Scholar
Hughes, J. D. et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18, 4872–4875 (2008).
留言 (0)